30 results found.

Idiopathic Pulmonary Fibrosis Clinical Trial using tralokinumab cohort 1; tralokinumab cohort 2; Placebo

AstraZeneca - Recruiting 50 years or older.
- A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis.
tralokinumab cohort 1; tralokinumab cohort 2; Placebo

Idiopathic Pulmonary Fibrosis Clinical Trial using Matching Placebo; Nintedanib

Boehringer Ingelheim - Recruiting 40 years or older.
- A Double Blind Randomized Placebo Controlled Trial Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Twelve Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months.
Matching Placebo; Nintedanib

Idiopathic Pulmonary Fibrosis Clinical Trial using Simtuzumab (GS-6624); Placebo

Gilead Sciences - Recruiting 45 years to 85 years.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
Simtuzumab (GS-6624); Placebo

Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pud Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Clinical and Basic Investigations Into Erdheim-Chester Disease.

Idiopathic Pulmonary Fibrosis Clinical Trial using BMS-986020; Placebo matching with BMS-986020

Bristol-Myers Squibb - Recruiting 40 years to 80 years.
- Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis.
BMS-986020; Placebo matching with BMS-986020

Idiopathic Pulmonary Fibrosis Clinical Trial using lebrikizumab; placebo

Hoffmann-La Roche - Recruiting 40 years or older.
- A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.
lebrikizumab; placebo

Asthma, or Pulmonary Fibrosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 65 years.
- Bronchoscopy in Patients With Pulmonary Diseases and Research Volunteers.

Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosi Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease.

Cystic Fibrosis Clinical Trial using Aztreonam for Inhalation Solution (AZLI); Placebo

Gilead Sciences - Recruiting 6 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis.
Aztreonam for Inhalation Solution (AZLI); Placebo

Pulmonary Fibrosis, or Lung Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 40 years to 80 years.
- Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease.

Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interst Clinical Trial using Aerobic Exercise Training

National Institutes of Health Clinical Center (CC) - Recruiting 21 years to 80 years.
- The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease.
Aerobic Exercise Training

Idiopathic Pulmonary Fibrosis Clinical Trial using FG-3019; Placebo

FibroGen - Recruiting 40 years to 80 years.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis.
FG-3019; Placebo

Albinism, Intestinal Disease, Kidney Disease, Myocardial Disease, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 80 years.
- Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome.

Lung Disease, Interstitial, or Idiopathic Pulmonary Fibrosis Clinical Trial

Ohio State University - Recruiting 18 years or older.
- Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

Bronchiectasis Clinical Trial using Ciprofloxacin DPI (BAYQ3939); Placebo

Bayer - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis..
Ciprofloxacin DPI (BAYQ3939); Placebo

Cystic Fibrosis Clinical Trial using Tobramycin Inhalation Powder

Novartis - Recruiting 6 years or older.
- A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis.
Tobramycin Inhalation Powder

Aplastic Anemia, Bone Marrow Failure Syndromes, Idiopathic Pulmon Clinical Trial using Nandrolone Decanoate

University of Sao Paulo - Recruiting 2 years or older.
- Male Hormones for Telomere Related Diseases.
Nandrolone Decanoate

Idiopathic Pulmonary Fibrosis Clinical Trial using Cotrimoxazole; Placebo

Fundaci¢n P£blica Andaluza para la gesti¢n de la Investigaci¢n en Sevilla - Recruiting 18 years to 80 years.
- Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis.
Cotrimoxazole; Placebo

Ambulatory IPF Clinical Trial using Rituximab; Placebo

University of Pittsburgh - Recruiting 50 years to 85 years.
- Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF).
Rituximab; Placebo

Idiopathic Pulmonary Fibrosis Clinical Trial using Tralokinumab; Placebo

MedImmune LLC - Recruiting 50 years to 79 years.
- A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis.
Tralokinumab; Placebo

Idiopathic Pulmonary Fibrosis Clinical Trial

University of Nottingham - Recruiting 18 years to 85 years.
- Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England).

Cystic Fibrosis Clinical Trial

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Extra Pulmonary Determinants of Physical Activity in Adults With Cystic Fibrosis..

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial using Allogeneic Adult Human Mesenchymal Stem Cells (MSCs); matched placebo

University of Miami - Recruiting 40 years to 86 years.
- A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis.
Allogeneic Adult Human Mesenchymal Stem Cells (MSCs); matched placebo

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial

University of California, San Francisco - Recruiting 35 years to 80 years.
- Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months..

Idiopathic Pulmonary Fibrosis Clinical Trial

University of California, San Francisco - Recruiting 18 years or older.
- The Role of Microaspiration in Idiopathic Pulmonary Fibrosis.

Pulmonary Fibrosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis.

Allergic Broncho-Pulmonary Aspergillosis Clinical Trial using Study of predictive factors

Nantes University Hospital - Recruiting 18 years or older.
- Interest of TARC Serum Marker for Follow-up of Patients With Allergic Broncho-Pulmonary Aspergillosis (ABPA), Excluding Cystic Fibrosis.
Study of predictive factors

Idiopathic Pulmonary Fibrosis Clinical Trial

University of Pittsburgh - Recruiting 18 years or older.
- The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry.

Pulmonary Fibrosis, or Breast Cancer Clinical Trial using Tamoxifen; Radiotherapy

Tata Memorial Hospital - Recruiting N/A or older.
- A Randomized Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy to Assess the Extent of Pulmonary Fibrosis and Disease Related Control and Survival in Breast Cancer Patients.
Tamoxifen; Radiotherapy

Idiopathic Pulmonary Fibrosis Clinical Trial using Placebo; AZAPRED

Thorax National Institute - Recruiting 45 years to 79 years.
- Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study.
Placebo; AZAPRED